Key Updates
British American Tobacco has declined -2.49% since the last report to £4,353, with YTD gains contracting to +3.30% from the previous +5.93%. The pullback reflects mounting regulatory pressure as over 160 health organizations demand Formula 1 terminate tobacco sponsorships, alongside shareholder litigation over North Korea sanctions breaches. The U.S. International Trade Commission has opened an investigation into illicit vaping products following BAT's complaint, which could reduce the illegal e-cigarette market by one-third if successful, though impacts are unlikely before 2027. Despite near-term headwinds, BAT's transformation thesis remains intact with Velo gaining U.S. market share against competitors.
Current Trend
BAT has experienced increased volatility over the past week, declining -6.19% over 5 days and -0.80% in the latest session. The stock has retraced from recent highs, with YTD performance moderating from +10.63% in late February to +3.30% currently. The 6-month performance of +5.32% indicates medium-term resilience, though recent momentum has deteriorated. The stock faces near-term resistance around the £4,500-£4,660 range established in late February, with current levels testing support near £4,350. Trading volumes have likely increased amid regulatory controversy and legal developments.
Investment Thesis
BAT's investment case centers on its transformation from traditional cigarettes to reduced-risk products, with new categories revenue growing 7% to £3.62 billion in 2025. The company delivered adjusted profit from operations of £11.89 billion, exceeding consensus estimates of £11.29 billion, while maintaining a 2% dividend increase to 245.04 pence per share. Velo nicotine pouches have gained U.S. market share against Philip Morris' Zyn through higher nicotine strengths and promotional strategies. The potential ITC exclusion order against unauthorized vapes could significantly improve BAT's competitive position in the U.S. e-cigarette market, where illegal products currently comprise approximately 70% of sales. However, the thesis faces headwinds from regulatory scrutiny of Formula 1 sponsorships, shareholder litigation over sanctions breaches, and the closure of South African manufacturing due to 75% illicit market penetration.
Thesis Status
The transformation thesis remains fundamentally intact but faces elevated execution risks. BAT's new categories growth of 7% and market share gains for Velo validate the strategic direction, while the potential ITC import block could be transformative for U.S. vape profitability. However, the timeline for regulatory relief has extended to 2027, delaying anticipated benefits. The Formula 1 sponsorship controversy introduces reputational risk and potential marketing restrictions that could constrain Velo's growth trajectory in key markets. Shareholder litigation over North Korea sanctions, while related to historical conduct, creates overhang and potential financial exposure. The South African factory closure, though operationally rational given 75% illicit market share, signals deteriorating conditions in emerging markets. Overall, the thesis faces a more challenging risk/reward profile than three weeks ago, with regulatory and legal uncertainties offsetting operational progress.
Key Drivers
Regulatory pressure has intensified as 162 health organizations called for Formula 1 to ban tobacco sponsorships, specifically targeting BAT's McLaren partnership promoting Velo nicotine pouches. The campaign highlights F1's youth audience of 4 million children aged 8-12 across the U.S. and EU, creating potential for marketing restrictions or partnership termination. Legal risks have materialized with over 100 shareholders filing a London High Court lawsuit regarding alleged failures to disclose North Korea sanctions breaches, following BAT's $635 million settlement with U.S. authorities in 2023. On the positive side, the ITC has opened an investigation into illicit vaping products following BAT's complaint, with the company estimating a potential one-third reduction in the illegal U.S. e-cigarette market. However, BAT's CEO indicated any impact is unlikely before 2027 due to long supply chains and existing inventories. Competitively, Philip Morris forecast 2026 adjusted EPS growth of 11.1%-13.1%, though Zyn faces market share pressure from BAT's Velo brand.
Technical Analysis
BAT has broken below the £4,500 support level established in early March, declining -6.19% over the past five days to £4,353. The stock established a YTD high near £4,660 in late February before entering a corrective phase. Current price action suggests testing of the £4,350 support zone, with further downside potentially targeting £4,200-£4,250. The 6-month gain of +5.32% indicates a longer-term uptrend remains intact, though near-term momentum has deteriorated sharply. Resistance now sits at £4,500, with stronger resistance at £4,660. The stock's volatility has increased significantly, with the -2.49% decline since the last report accelerating the -2.21% and -2.08% declines in prior sessions, indicating sustained selling pressure rather than isolated weakness.
Bull Case
- ITC investigation could eliminate one-third of illegal U.S. vape market: BAT estimates unauthorized devices comprise 70% of U.S. e-cigarette sales, negatively affecting both vape and traditional tobacco businesses. A successful ITC exclusion order could significantly improve market dynamics and profitability, with full determination expected in March. Source: Reuters
- Velo gaining U.S. market share against Zyn: BAT's Velo nicotine pouch brand has captured market share from competitors Altria's On! and Philip Morris' Zyn through higher nicotine strengths and promotional offers, validating the company's competitive strategy in the fastest-growing reduced-risk category. Source: Reuters
- Strong 2025 financial performance exceeding estimates: Adjusted profit from operations reached £11.89 billion, surpassing consensus forecasts of £11.29 billion, while pretax profit surged to £9.86 billion from £3.54 billion year-over-year. New categories revenue grew 7% to £3.62 billion, demonstrating successful transformation execution. Source: Wall Street Journal
- Maintained dividend growth trajectory: The board declared a dividend of 245.04 pence per share, representing a 2% year-on-year increase, demonstrating confidence in cash generation and commitment to shareholder returns despite transformation investments. Source: Morningstar
- Philip Morris facing competitive pressure on Zyn: PMI shares fell 2.9% despite beating profit forecasts due to competitive pressures on its Zyn brand, which saw U.S. volumes grow only 19% in Q4 while facing market share losses to rivals including BAT, indicating BAT's competitive positioning is strengthening. Source: Reuters
Bear Case
- Formula 1 sponsorship under regulatory assault: Over 160 health organizations have called for F1 to terminate tobacco sponsorships, with BAT's McLaren partnership promoting Velo to F1's youth audience of 4 million children aged 8-12. The campaign includes pressure on Disney, Lego, and Mattel to force F1's hand, creating significant risk of marketing restrictions or partnership termination. Source: Reuters
- Shareholder litigation over North Korea sanctions breaches: Over 100 current and former shareholders filed a London High Court lawsuit regarding alleged failures to properly disclose sanctions violations to the stock market, following BAT's $635 million settlement with U.S. authorities in 2023 for operations between 2007-2017, creating financial and reputational overhang. Source: Reuters
- ITC relief delayed until 2027 at earliest: Despite favorable ITC judge ruling and ongoing investigation, BAT's CEO stated any impact from import blocks on unauthorized vapes is unlikely before 2027 due to long supply chains and large existing inventories, extending the period of competitive disadvantage in the U.S. vape market. Source: Reuters
- South African factory closure signals emerging market deterioration: BAT announced closure of its sole South African factory by year-end after illicit cigarettes reached 75% of the traditional cigarette market, resulting in approximately 230 job losses and highlighting vulnerability to illegal trade in key emerging markets. Source: Bloomberg
- Overall revenue declined 1% despite new categories growth: Total group revenue fell to £25.61 billion from higher prior-year levels, with a 3.1% foreign exchange headwind offsetting operational gains, while vape volumes declined nearly 13% in 2025 due to illegal product sales in the U.S. and Canada. Source: Wall Street Journal